Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $815000.0.

  • Janux Therapeutics' Gains from Investment Securities fell 9137.29% to $815000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $33.8 million, marking a year-over-year increase of 13678.01%. This contributed to the annual value of $8.9 million for FY2024, which is 1106.34% up from last year.
  • Latest data reveals that Janux Therapeutics reported Gains from Investment Securities of $815000.0 as of Q3 2025, which was down 9137.29% from -$9000.0 recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Gains from Investment Securities ranged from a high of $23.5 million in Q4 2024 and a low of -$1.1 million during Q2 2024
  • Its 5-year average for Gains from Investment Securities is $4.8 million, with a median of $3.3 million in 2021.
  • Per our database at Business Quant, Janux Therapeutics' Gains from Investment Securities crashed by 210000.0% in 2022 and then surged by 773333.33% in 2024.
  • Over the past 5 years, Janux Therapeutics' Gains from Investment Securities (Quarter) stood at $5.5 million in 2021, then tumbled by 93.8% to $344000.0 in 2022, then decreased by 12.79% to $300000.0 in 2023, then skyrocketed by 7733.33% to $23.5 million in 2024, then plummeted by 96.53% to $815000.0 in 2025.
  • Its Gains from Investment Securities was $815000.0 in Q3 2025, compared to -$9000.0 in Q2 2025 and $10.0 million in Q1 2025.